News
The National Cancer Institute’s Clinical Proteomic Technologies for Cancer (CPTC) initiative has recognized Allele Biotech’s contribution to special antibodies. In an interview with ProteoMonitor, the Director of the NCI program mentioned Allele Biotech’s project as 1 of the 2 examples of ongoing successes under the program. With only 6 months, the Allele/AvantGen team was able to effectively isolate and express monoclonal level or better antibodies against 8 cancer antigents. Against each target the antibodies were developed in more than one pair, of which any antibody can be converted to mouse, rat, goat, or any species specificity. The antibodies’ properties have been well-characterized and ready for ELISA and other detection technologies.
According to the interview, the NCI’s CPTC Program is now moving onto the next phase of its efforts to improve proteomics research by turning its attention to the vendor community: Its aim is to get those tools into the research community, and to invest commercial players more heavily into CPTC’s efforts. Allele Biotech has been invited to submit for a $1,000,000 second phase proposal to work on more than 100 cancer antigents starting next summer, again in collaboration with AvantGen, an independent company residing within Allele’s research facility.
.
|